Lim Yik Hew
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lim Yik Hew has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Norikazu Isoda
Laboratory of Microbiology, Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan
9 shared publications - Takahiro Hiono
Laboratory of Microbiology, Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University
9 shared publications - Yoshihiro Sakoda
Hokkaido University
7 shared publications - Loc Tan Huynh
Laboratory of Microbiology, Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-Ku, Sapporo 060-0818, Hokkaido, Japan
6 shared publications - Daiki Kobayashi
Laboratory of Microbiology, Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University
4 shared publications - Maya Kobayashi
Laboratory of Microbiology, Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan
3 shared publications
Latest Publications
- Open Access
Efficacy and Limitations of an Improved Vaccine Derived from an Updated Vaccine Strain Against H5 High Pathogenicity Avian Influenza
Background/Objectives: Biosecurity and stamping out are key control measures against H5 high pathogenicity avian influenza (HPAI) outbreaks. Vaccination in poultry is an additional tool to reduce disease risk and facilitate timely containment. This study aimed to establish a candidate vaccine strain against H5 HPAI in Asia and validate its protective efficacy. Methods: Based on genetic and antigenic analyses, a representative HPAI virus, A/duck/Vietnam/HU16-DD3/2023 (H5N1), collected in northern Vietnam, was selected to generate a candidate vaccine strain, rgPR8/VN23HA∆KRRK-NA (rgPR8/VN23; H5N1), using reverse genetics, followed by formulation of an inactivated oil-adjuvanted vaccine. Vaccine efficacy was evaluated by measuring humoral antibody responses after intramuscular vaccination and by assessing mortality and virus recovery following intranasal challenge with a clade 2.3.4.4b virus, A/Ezo red fox/Hokkaido/1/2022 (H5N1). Results were compared with those obtained using an antigenically homologous vaccine to the challenge strain and a Japanese stockpiled vaccine. Results: All vaccinated juvenile chickens developed sufficient immunity to survive the challenge at 21 days post-vaccination. The rgPR8/VN23 (H5N1) and homologous vaccines markedly reduced virus recovery, suggesting near-sterile protection, whereas low-titer viruses were transiently detected in chickens vaccinated with the stockpiled vaccine. The rgPR8/VN23 (H5N1) vaccine conferred clinical protection in juvenile chickens as early as 8 days post-vaccination. A single dose of the rgPR8/VN23 (H5N1) vaccine provided incomplete protection in laying hens, whereas a double-volume regimen improved protective efficacy. Conclusions: The rgPR8/VN23 (H5N1) vaccine conferred strong immunity to juvenile chickens; however, a refined vaccination strategy may be required to achieve complete protection in laying hens.
Open AccessEfficacy and Limitations of an Improved Vaccine Derived from an Updated Vaccine Strain Against H5 High Pathogenicity Avian Influenza
Background/Objectives: Biosecurity and stamping out are key control measures against H5 high pathogenicity avian influenza (HPAI) outbreaks. Vaccination in poultry is an additional tool to reduce disease risk and facilitate timely containment. This study aimed to establish a candidate vaccine strain against H5 HPAI in Asia and validate its protective efficacy. Methods: Based on genetic and antigenic analyses, a representative HPAI virus, A/duck/Vietnam/HU16-DD3/2023 (H5N1), collected in northern Vietnam, was selected to generate a candidate vaccine strain, rgPR8/VN23HA∆KRRK-NA (rgPR8/VN23; H5N1), using reverse genetics, followed by formulation of an inactivated oil-adjuvanted vaccine. Vaccine efficacy was evaluated by measuring humoral antibody responses after intramuscular vaccination and by assessing mortality and virus recovery following intranasal challenge with a clade 2.3.4.4b virus, A/Ezo red fox/Hokkaido/1/2022 (H5N1). Results were compared with those obtained using an antigenically homologous vaccine to the challenge strain and a Japanese stockpiled vaccine. Results: All vaccinated juvenile chickens developed sufficient immunity to survive the challenge at 21 days post-vaccination. The rgPR8/VN23 (H5N1) and homologous vaccines markedly reduced virus recovery, suggesting near-sterile protection, whereas low-titer viruses were transiently detected in chickens vaccinated with the stockpiled vaccine. The rgPR8/VN23 (H5N1) vaccine conferred clinical protection in juvenile chickens as early as 8 days post-vaccination. A single dose of the rgPR8/VN23 (H5N1) vaccine provided incomplete protection in laying hens, whereas a double-volume regimen improved protective efficacy. Conclusions: The rgPR8/VN23 (H5N1) vaccine conferred strong immunity to juvenile chickens; however, a refined vaccination strategy may be required to achieve complete protection in laying hens.
- Open Access
- 19 January 2026
- Published by Oxford University Press (OUP) in Virus Evolution
- Vol. 12 (1)
Introduction and inter-species transmission dynamics of high pathogenicity avian influenza H5N1 viruses in Japan 2021–25
High pathogenicity avian influenza virus impacts poultry and wild birds worldwide. Since the introduction of clade 2.3.4.4b H5N1 isolates in Japan in late 2021, new cases have been reported in domestic birds and poultry each winter. To understand the role of wild birds in introducing these viruses in Japan, a phylodynamic analysis based on geography and host species was conducted using H5N1 isolates in Japan from 2021 to 2025. A total of 892 hemagglutinin gene sequences of H5N1 viruses, collected from birds between June 2021 and May 2025, along with additional sequences that were highly similar to those of Japanese isolates, were obtained from a public database. The role of wild birds in the transmission dynamics of H5N1 isolates in Japan across four winter seasons (2021–25) was assessed using a Bayesian phylodynamic approach with a Multi-Type Birth-Death model. Phylodynamic analysis revealed that the clade 2.3.4.4b comprised three distinct subgroups, G2b, G2c, and G2d, which were prevalent during the winter seasons. Isolates from G2b and G2c were linked to common ancestral strains from North Asia and Northeast Asia, respectively. Meanwhile, G2d, the dominant strain in Japan from 2021 to 2025, shared an ancestral strain from the Northwest America. During winters 2023–25, the ancestral strain was traced back to Northeast Asia, indicating a shift in the viral origin. This transition suggests an increase in virus migration events and expansion of host diversity, implying that Japan may function as a hub for intercontinental virus introductions, receiving multiple independent viral entries from North Asia, Northeast Asia, and Northwest America. Additionally, waterfowl and raptors played a role in introducing viruses into Japan, while poultry and crows generally serving as dead-end hosts. However, the continuous introduction of H5N1 isolates into Japan each winter can alter the disease transmission pattern observed in crows, resulting in more virus spillover from crows to other hosts, such as poultry and charadriiformes. These findings emphasize the importance of continuous monitoring and prompt information sharing to understand the global dynamics of viruses better.
- 19 January 2026
- Published by Oxford University Press (OUP) in Virus Evolution
- Vol. 12 (1)
Open AccessIntroduction and inter-species transmission dynamics of high pathogenicity avian influenza H5N1 viruses in Japan 2021–25
High pathogenicity avian influenza virus impacts poultry and wild birds worldwide. Since the introduction of clade 2.3.4.4b H5N1 isolates in Japan in late 2021, new cases have been reported in domestic birds and poultry each winter. To understand the role of wild birds in introducing these viruses in Japan, a phylodynamic analysis based on geography and host species was conducted using H5N1 isolates in Japan from 2021 to 2025. A total of 892 hemagglutinin gene sequences of H5N1 viruses, collected from birds between June 2021 and May 2025, along with additional sequences that were highly similar to those of Japanese isolates, were obtained from a public database. The role of wild birds in the transmission dynamics of H5N1 isolates in Japan across four winter seasons (2021–25) was assessed using a Bayesian phylodynamic approach with a Multi-Type Birth-Death model. Phylodynamic analysis revealed that the clade 2.3.4.4b comprised three distinct subgroups, G2b, G2c, and G2d, which were prevalent during the winter seasons. Isolates from G2b and G2c were linked to common ancestral strains from North Asia and Northeast Asia, respectively. Meanwhile, G2d, the dominant strain in Japan from 2021 to 2025, shared an ancestral strain from the Northwest America. During winters 2023–25, the ancestral strain was traced back to Northeast Asia, indicating a shift in the viral origin. This transition suggests an increase in virus migration events and expansion of host diversity, implying that Japan may function as a hub for intercontinental virus introductions, receiving multiple independent viral entries from North Asia, Northeast Asia, and Northwest America. Additionally, waterfowl and raptors played a role in introducing viruses into Japan, while poultry and crows generally serving as dead-end hosts. However, the continuous introduction of H5N1 isolates into Japan each winter can alter the disease transmission pattern observed in crows, resulting in more virus spillover from crows to other hosts, such as poultry and charadriiformes. These findings emphasize the importance of continuous monitoring and prompt information sharing to understand the global dynamics of viruses better.
- Open Access
- 18 December 2025
- Published by MDPI AG in Preprints.org
Efficacy and Limitations of an Improved Vaccine Derived from an Updated Vaccine Strain Against H5 High Pathogenicity Avian Influenza
Although biosecurity and stamping out are key control measures, vaccination in poultry is an additional tool against H5 high pathogenicity avian influenza (HPAI) outbreaks to reduce disease risk and facilitate timely containment. This study aims to establish a candidate vaccine strain against H5 HPAI in Asia and validate its protective efficacy. Based on genetic and antigenic analyses, A/duck/Vietnam/HU16-DD3/2023 (H5N1), collected in northern Vietnam, was selected for establishing the vaccine candidate strain. The vaccine strain, rgPR8/VN23HA∆KRRK-NA (H5N1; rgPR8/VN23), was generated. Inactivated oil-adjuvanted vaccines were prepared from rgPR8/VN23 (H5N1), NIID-002 (H5N1), which originated from HPAI virus, A/Ezo red fox/Hokkaido/1/2022 (H5N1; Fox/Hok/1/22), and a Japanese stockpiled vaccine strain with a distinct antigen. These vaccines were intramuscularly injected into juvenile chickens or adult laying hens. All vaccinated juvenile chickens acquired optimal immunity and survived for 14 days after intranasal challenge with Fox/Hok/1/22 at 21 days post-vaccination (dpv). The rgPR8/VN23 and NIID-002 vaccines markedly reduced virus shedding, suggesting near-sterile protection. However, low-titer viruses were transiently detected in chickens vaccinated with the stockpiled vaccine strain. The rgPR8/VN23 vaccine induced immunity in juvenile chickens against Fox/Hok/1/22 as early as 8 dpv. Intriguingly, a single dose of vaccine was insufficient to provide protective immunity to laying hens. Protective efficacy increased with a double-volume dose vaccine. These data confirm that the antigenicity-matched vaccine conferred sterilized immunity in 21 days and clinical protection in 8 days to juvenile chickens, although complete protection of hens may require a refined vaccination strategy.
- 18 December 2025
- Published by MDPI AG in Preprints.org
Open AccessEfficacy and Limitations of an Improved Vaccine Derived from an Updated Vaccine Strain Against H5 High Pathogenicity Avian Influenza
Although biosecurity and stamping out are key control measures, vaccination in poultry is an additional tool against H5 high pathogenicity avian influenza (HPAI) outbreaks to reduce disease risk and facilitate timely containment. This study aims to establish a candidate vaccine strain against H5 HPAI in Asia and validate its protective efficacy. Based on genetic and antigenic analyses, A/duck/Vietnam/HU16-DD3/2023 (H5N1), collected in northern Vietnam, was selected for establishing the vaccine candidate strain. The vaccine strain, rgPR8/VN23HA∆KRRK-NA (H5N1; rgPR8/VN23), was generated. Inactivated oil-adjuvanted vaccines were prepared from rgPR8/VN23 (H5N1), NIID-002 (H5N1), which originated from HPAI virus, A/Ezo red fox/Hokkaido/1/2022 (H5N1; Fox/Hok/1/22), and a Japanese stockpiled vaccine strain with a distinct antigen. These vaccines were intramuscularly injected into juvenile chickens or adult laying hens. All vaccinated juvenile chickens acquired optimal immunity and survived for 14 days after intranasal challenge with Fox/Hok/1/22 at 21 days post-vaccination (dpv). The rgPR8/VN23 and NIID-002 vaccines markedly reduced virus shedding, suggesting near-sterile protection. However, low-titer viruses were transiently detected in chickens vaccinated with the stockpiled vaccine strain. The rgPR8/VN23 vaccine induced immunity in juvenile chickens against Fox/Hok/1/22 as early as 8 dpv. Intriguingly, a single dose of vaccine was insufficient to provide protective immunity to laying hens. Protective efficacy increased with a double-volume dose vaccine. These data confirm that the antigenicity-matched vaccine conferred sterilized immunity in 21 days and clinical protection in 8 days to juvenile chickens, although complete protection of hens may require a refined vaccination strategy.
- Open Access
Genetic Diversity of Highly Pathogenic Avian Influenza Viruses Isolated in Hokkaido, Japan, During Winter 2024–2025
Genetic and antigenic analyses were performed on highly pathogenic avian influenza viruses (HPAIVs) isolated in Hokkaido, northern Japan, during the winter of 2024–2025. Ninety-eight HPAIVs were isolated from feces of waterfowl, tracheal swabs from dead wild birds, or lung homogenates from dead chickens. Phylogenetic analysis of the hemagglutinin (HA) gene from 47 representative isolates revealed that all sequences belonged to the G2d subgroup of clade 2.3.4.4b H5HA, which has been the dominant lineage in Hokkaido since the winter of 2021–2022. These isolates were further divided into three major groups within the subgroup. The HPAIVs isolated in the Republic of Korea, China, and North America were genetically closely related to the Hokkaido isolates, whereas no HPAIVs genetically related to European strains or those detected in North American cattle were identified. Furthermore, HPAIVs isolated from seabirds were genetically closely related to those found in dead marine mammals along the eastern coast of Hokkaido in the spring of 2025. No apparent antigenic differences were observed between the HPAIVs isolated in this study and those from previous seasons. These findings highlight the wide distribution of HPAIVs in Hokkaido, particularly from Asian and North American lineages, and underscore the importance of continuous surveillance.
Open AccessGenetic Diversity of Highly Pathogenic Avian Influenza Viruses Isolated in Hokkaido, Japan, During Winter 2024–2025
Genetic and antigenic analyses were performed on highly pathogenic avian influenza viruses (HPAIVs) isolated in Hokkaido, northern Japan, during the winter of 2024–2025. Ninety-eight HPAIVs were isolated from feces of waterfowl, tracheal swabs from dead wild birds, or lung homogenates from dead chickens. Phylogenetic analysis of the hemagglutinin (HA) gene from 47 representative isolates revealed that all sequences belonged to the G2d subgroup of clade 2.3.4.4b H5HA, which has been the dominant lineage in Hokkaido since the winter of 2021–2022. These isolates were further divided into three major groups within the subgroup. The HPAIVs isolated in the Republic of Korea, China, and North America were genetically closely related to the Hokkaido isolates, whereas no HPAIVs genetically related to European strains or those detected in North American cattle were identified. Furthermore, HPAIVs isolated from seabirds were genetically closely related to those found in dead marine mammals along the eastern coast of Hokkaido in the spring of 2025. No apparent antigenic differences were observed between the HPAIVs isolated in this study and those from previous seasons. These findings highlight the wide distribution of HPAIVs in Hokkaido, particularly from Asian and North American lineages, and underscore the importance of continuous surveillance.
- Open Access
Generation of Vaccine Candidate Strains That Antigenically Match Classical Swine Fever Virus Field Strains
Background: Classical swine fever virus (CSFV) is genetically categorized into three genotypes. A live-attenuated vaccine strain GPE−, currently used in Japan, belongs to genotype 1 and is genetically distinct from the field strains circulating in Japan, which belong to genotype 2. This study aimed to understand the antigenicity of recent field isolates in Japan and develop new vaccine candidates that antigenically match field strains. Methods: The serum samples of 20 pigs vaccinated with GPE− were subjected to a serum neutralizing test (SNT) using one of the field strains, CSFV/wb/Jpn-Mie/P96/2019 (Mie/2019). For the antigenic matching, vGPE−/HiBiT/Mie E2 was generated by replacing the viral glycoprotein E2, the main target of the neutralizing antibody, with that of Mie/2019. Additionally, vGPE−/HiBiT/Mie E2/PAPeV Erns was generated by further substituting glycoprotein Erns with that of pronghorn antelope pestivirus (PAPeV) since Erns is not important as a vaccine immunogen and can be replaced by that of other pestiviruses to provide an immunological marker. The efficacy of vGPE−/HiBiT/Mie E2/PAPeV Erns was further evaluated by the challenge experiments in pigs. Results: The SNT titers of serum sample against Mie/2019 were 6.1-fold lower than that against vGPE−. The generated recombinant viruses showed closer antigenicity to Mie/2019 than vGPE−. The challenge study confirmed that vGPE−/HiBiT/Mie E2/PAPeV Erns provided clinical and virological protection against a field CSFV equivalent to vGPE−. Conclusions: This study demonstrated that swapping the E2 encoding region with the prevalent field CSFVs is a promising strategy to achieve antigenic matching between the vaccine and field strains.
Open AccessGeneration of Vaccine Candidate Strains That Antigenically Match Classical Swine Fever Virus Field Strains
Background: Classical swine fever virus (CSFV) is genetically categorized into three genotypes. A live-attenuated vaccine strain GPE−, currently used in Japan, belongs to genotype 1 and is genetically distinct from the field strains circulating in Japan, which belong to genotype 2. This study aimed to understand the antigenicity of recent field isolates in Japan and develop new vaccine candidates that antigenically match field strains. Methods: The serum samples of 20 pigs vaccinated with GPE− were subjected to a serum neutralizing test (SNT) using one of the field strains, CSFV/wb/Jpn-Mie/P96/2019 (Mie/2019). For the antigenic matching, vGPE−/HiBiT/Mie E2 was generated by replacing the viral glycoprotein E2, the main target of the neutralizing antibody, with that of Mie/2019. Additionally, vGPE−/HiBiT/Mie E2/PAPeV Erns was generated by further substituting glycoprotein Erns with that of pronghorn antelope pestivirus (PAPeV) since Erns is not important as a vaccine immunogen and can be replaced by that of other pestiviruses to provide an immunological marker. The efficacy of vGPE−/HiBiT/Mie E2/PAPeV Erns was further evaluated by the challenge experiments in pigs. Results: The SNT titers of serum sample against Mie/2019 were 6.1-fold lower than that against vGPE−. The generated recombinant viruses showed closer antigenicity to Mie/2019 than vGPE−. The challenge study confirmed that vGPE−/HiBiT/Mie E2/PAPeV Erns provided clinical and virological protection against a field CSFV equivalent to vGPE−. Conclusions: This study demonstrated that swapping the E2 encoding region with the prevalent field CSFVs is a promising strategy to achieve antigenic matching between the vaccine and field strains.
- Open Access
Assessment of the Safety Profile of Chimeric Marker Vaccine against Classical Swine Fever: Reversion to Virulence Study
Chimeric marker vaccine candidates, vGPE−/PAPeV Erns and vGPE−/PhoPeV Erns, have been generated and their efficacy and capability to differentiate infected from vaccinated animals were confirmed in previous studies. The safety profile of the two chimeric marker vaccine candidates, particularly in the potential reversion to virulence, was evaluated. Each virus was administered to pigs with a dose equivalent to the vaccination dose, and pooled tonsil homogenates were subsequently inoculated into further pigs. Chimeric virus vGPE−/PAPeV Erns displayed the most substantial attenuation, achieving this within only two passages, whereas vGPE−/PhoPeV Erns was detectable until the third passage and disappeared entirely by the fourth passage. The vGPE− strain, assessed alongside, consistently exhibited stable virus recovery across each passage without any signs of increased virulence in pigs. In vitro assays revealed that the type I interferon-inducing capacity of vGPE−/PAPeV Erns was significantly higher than that of vGPE−/PhoPeV Erns and vGPE−. In conclusion, the safety profile of the two chimeric marker vaccine candidates was affirmed. Further research is essential to ensure the stability of their attenuation and safety in diverse pig populations.
Open AccessAssessment of the Safety Profile of Chimeric Marker Vaccine against Classical Swine Fever: Reversion to Virulence Study
Chimeric marker vaccine candidates, vGPE−/PAPeV Erns and vGPE−/PhoPeV Erns, have been generated and their efficacy and capability to differentiate infected from vaccinated animals were confirmed in previous studies. The safety profile of the two chimeric marker vaccine candidates, particularly in the potential reversion to virulence, was evaluated. Each virus was administered to pigs with a dose equivalent to the vaccination dose, and pooled tonsil homogenates were subsequently inoculated into further pigs. Chimeric virus vGPE−/PAPeV Erns displayed the most substantial attenuation, achieving this within only two passages, whereas vGPE−/PhoPeV Erns was detectable until the third passage and disappeared entirely by the fourth passage. The vGPE− strain, assessed alongside, consistently exhibited stable virus recovery across each passage without any signs of increased virulence in pigs. In vitro assays revealed that the type I interferon-inducing capacity of vGPE−/PAPeV Erns was significantly higher than that of vGPE−/PhoPeV Erns and vGPE−. In conclusion, the safety profile of the two chimeric marker vaccine candidates was affirmed. Further research is essential to ensure the stability of their attenuation and safety in diverse pig populations.
- Open Access
- 1 January 2024
- Published by Wiley in Transboundary and Emerging Diseases
- Vol. 2024 (1)
Continuous Introduction of H5 High Pathogenicity Avian Influenza Viruses in Hokkaido, Japan: Characterization of Viruses Isolated in Winter 2022–2023 and Early Winter 2023–2024
High pathogenicity avian influenza (HPAI) has impacted poultry and wild birds globally. The number of H5 HPAI virus (HPAIV) infection cases in wild birds in Hokkaido (Northern Japan) was high in the last two seasons, contributing to virus spillover to resident birds and poultry. Therefore, H5 HPAIVs in birds and mammals in Hokkaido in winter 2022–2023 and 2023–2024 were monitored and viruses were phylogenetically, antigenically, and pathogenetically characterized. Thirty HPAIV isolates were subtyped and pathotyped by sequencing the hemagglutinin (HA) gene of viruses. Phylogenetic analysis of the HA gene revealed that all isolated HPAIVs were categorized into clade 2.3.4.4b and divided into three groups (G2b, G2c, and G2d). Most isolates belonging to subgroup G2d clustered with isolates in winter 2021–2022 in Hokkaido. The other isolates were categorized into two subgroups, G2b and G2c, mainly composed of isolates in Honshu Island in winter 2021–2022 and 2022–2023, respectively. Two H5 HPAIVs isolated in Eastern Russia in spring and autumn 2022 were genetically close to most Hokkaido isolates (G2d), and a virus isolated in Hokkaido in November 2023 was also grouped in subgroup G2d. Further analysis of all eight gene segments identified six types of gene constellations. Cross‐hemagglutination inhibition test indicated that the antigenicity of H5 HPAIVs isolated in the last several seasons was similar within them but slightly different from that in the 2010s. Three chicken breeds were intranasally challenged with four representative isolates to assess their pathogenicity. All chickens except one broiler chicken were dead until 5‐day postchallenge with different pathogenicity of these viruses. The pathogenicity of one HPAIV strain was significantly lower in broiler chickens than in layer chickens. The mixture of multiple characteristics of HPAIVs in Hokkaido was confirmed by bird migration routes. Thus, many HPAIVs can be brought and scattered anywhere on Earth.
- 1 January 2024
- Published by Wiley in Transboundary and Emerging Diseases
- Vol. 2024 (1)
Open AccessContinuous Introduction of H5 High Pathogenicity Avian Influenza Viruses in Hokkaido, Japan: Characterization of Viruses Isolated in Winter 2022–2023 and Early Winter 2023–2024
High pathogenicity avian influenza (HPAI) has impacted poultry and wild birds globally. The number of H5 HPAI virus (HPAIV) infection cases in wild birds in Hokkaido (Northern Japan) was high in the last two seasons, contributing to virus spillover to resident birds and poultry. Therefore, H5 HPAIVs in birds and mammals in Hokkaido in winter 2022–2023 and 2023–2024 were monitored and viruses were phylogenetically, antigenically, and pathogenetically characterized. Thirty HPAIV isolates were subtyped and pathotyped by sequencing the hemagglutinin (HA) gene of viruses. Phylogenetic analysis of the HA gene revealed that all isolated HPAIVs were categorized into clade 2.3.4.4b and divided into three groups (G2b, G2c, and G2d). Most isolates belonging to subgroup G2d clustered with isolates in winter 2021–2022 in Hokkaido. The other isolates were categorized into two subgroups, G2b and G2c, mainly composed of isolates in Honshu Island in winter 2021–2022 and 2022–2023, respectively. Two H5 HPAIVs isolated in Eastern Russia in spring and autumn 2022 were genetically close to most Hokkaido isolates (G2d), and a virus isolated in Hokkaido in November 2023 was also grouped in subgroup G2d. Further analysis of all eight gene segments identified six types of gene constellations. Cross‐hemagglutination inhibition test indicated that the antigenicity of H5 HPAIVs isolated in the last several seasons was similar within them but slightly different from that in the 2010s. Three chicken breeds were intranasally challenged with four representative isolates to assess their pathogenicity. All chickens except one broiler chicken were dead until 5‐day postchallenge with different pathogenicity of these viruses. The pathogenicity of one HPAIV strain was significantly lower in broiler chickens than in layer chickens. The mixture of multiple characteristics of HPAIVs in Hokkaido was confirmed by bird migration routes. Thus, many HPAIVs can be brought and scattered anywhere on Earth.
- Open Access
Generation and Efficacy of Two Chimeric Viruses Derived from GPE− Vaccine Strain as Classical Swine Fever Vaccine Candidates
A previous study proved that vGPE− mainly maintains the properties of classical swine fever (CSF) virus, which is comparable to the GPE− vaccine seed and is a potentially valuable backbone for developing a CSF marker vaccine. Chimeric viruses were constructed based on an infectious cDNA clone derived from the live attenuated GPE− vaccine strain as novel CSF vaccine candidates that potentially meet the concept of differentiating infected from vaccinated animals (DIVA) by substituting the glycoprotein Erns of the GPE− vaccine strain with the corresponding region of non-CSF pestiviruses, either pronghorn antelope pestivirus (PAPeV) or Phocoena pestivirus (PhoPeV). High viral growth and genetic stability after serial passages of the chimeric viruses, namely vGPE−/PAPeV Erns and vGPE−/PhoPeV Erns, were confirmed in vitro. In vivo investigation revealed that two chimeric viruses had comparable immunogenicity and safety profiles to the vGPE− vaccine strain. Vaccination at a dose of 104.0 TCID50 with either vGPE−/PAPeV Erns or vGPE−/PhoPeV Erns conferred complete protection for pigs against the CSF virus challenge in the early stage of immunization. In conclusion, the characteristics of vGPE−/PAPeV Erns and vGPE−/PhoPeV Erns affirmed their properties, as the vGPE− vaccine strain, positioning them as ideal candidates for future development of a CSF marker vaccine.
Open AccessGeneration and Efficacy of Two Chimeric Viruses Derived from GPE− Vaccine Strain as Classical Swine Fever Vaccine Candidates
A previous study proved that vGPE− mainly maintains the properties of classical swine fever (CSF) virus, which is comparable to the GPE− vaccine seed and is a potentially valuable backbone for developing a CSF marker vaccine. Chimeric viruses were constructed based on an infectious cDNA clone derived from the live attenuated GPE− vaccine strain as novel CSF vaccine candidates that potentially meet the concept of differentiating infected from vaccinated animals (DIVA) by substituting the glycoprotein Erns of the GPE− vaccine strain with the corresponding region of non-CSF pestiviruses, either pronghorn antelope pestivirus (PAPeV) or Phocoena pestivirus (PhoPeV). High viral growth and genetic stability after serial passages of the chimeric viruses, namely vGPE−/PAPeV Erns and vGPE−/PhoPeV Erns, were confirmed in vitro. In vivo investigation revealed that two chimeric viruses had comparable immunogenicity and safety profiles to the vGPE− vaccine strain. Vaccination at a dose of 104.0 TCID50 with either vGPE−/PAPeV Erns or vGPE−/PhoPeV Erns conferred complete protection for pigs against the CSF virus challenge in the early stage of immunization. In conclusion, the characteristics of vGPE−/PAPeV Erns and vGPE−/PhoPeV Erns affirmed their properties, as the vGPE− vaccine strain, positioning them as ideal candidates for future development of a CSF marker vaccine.
- Open Access
Detection of New H5N1 High Pathogenicity Avian Influenza Viruses in Winter 2021–2022 in the Far East, Which Are Genetically Close to Those in Europe
Many high pathogenicity avian influenza (HPAI) cases in wild birds due to H5N1 HPAI virus (HPAIV) infection were reported in northern Japan in the winter of 2021–2022. To investigate the epidemiology of HPAIVs brought to Japan from surrounding areas, a genetic analysis of H5 HPAIVs isolated in northern Japan was performed, and the pathogenicity of the HPAIV in chickens was assessed by experimental infection. Based on the genetic analysis of the hemagglutinin gene, pathogenic viruses detected in northern Japan as well as one in Sakhalin, the eastern part of Russia, were classified into the same subgroup as viruses prevalent in Europe in the same season but distinct from those circulating in Asia in winter 2020–2021. High identities of all eight segment sequences of A/crow/Hokkaido/0103B065/2022 (H5N1) (Crow/Hok), the representative isolates in northern Japan in 2022, to European isolates in the same season could also certify the unlikeliness of causing gene reassortment between H5 HPAIVs and viruses locally circulating in Asia. According to intranasal challenge results in six-week-old chickens, 50% of the chicken-lethal dose of Crow/Hok was calculated as 104.5 times of the 50% egg-infectious dose. These results demonstrated that the currently prevalent H5 HPAIVs could spread widely from certain origins throughout the Eurasian continent, including Europe and the Far East, and implied a possibility that contagious viruses are gathered in lakes in the northern territory via bird migration. Active monitoring of wild birds at the global level is essential to estimate the geographical source and spread dynamics of HPAIVs.
Open AccessDetection of New H5N1 High Pathogenicity Avian Influenza Viruses in Winter 2021–2022 in the Far East, Which Are Genetically Close to Those in Europe
Many high pathogenicity avian influenza (HPAI) cases in wild birds due to H5N1 HPAI virus (HPAIV) infection were reported in northern Japan in the winter of 2021–2022. To investigate the epidemiology of HPAIVs brought to Japan from surrounding areas, a genetic analysis of H5 HPAIVs isolated in northern Japan was performed, and the pathogenicity of the HPAIV in chickens was assessed by experimental infection. Based on the genetic analysis of the hemagglutinin gene, pathogenic viruses detected in northern Japan as well as one in Sakhalin, the eastern part of Russia, were classified into the same subgroup as viruses prevalent in Europe in the same season but distinct from those circulating in Asia in winter 2020–2021. High identities of all eight segment sequences of A/crow/Hokkaido/0103B065/2022 (H5N1) (Crow/Hok), the representative isolates in northern Japan in 2022, to European isolates in the same season could also certify the unlikeliness of causing gene reassortment between H5 HPAIVs and viruses locally circulating in Asia. According to intranasal challenge results in six-week-old chickens, 50% of the chicken-lethal dose of Crow/Hok was calculated as 104.5 times of the 50% egg-infectious dose. These results demonstrated that the currently prevalent H5 HPAIVs could spread widely from certain origins throughout the Eurasian continent, including Europe and the Far East, and implied a possibility that contagious viruses are gathered in lakes in the northern territory via bird migration. Active monitoring of wild birds at the global level is essential to estimate the geographical source and spread dynamics of HPAIVs.